AXSM — Axsome Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1579428 ·
Last close
$135.95
Market Cap
$7.15B
52W High
$260.19
52W Low
$123.00
ADV30
1,058,247
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 259,691,000 | 241,887,000 | -13,448,000 | -12,877,000 | 826,773,000 | 313,859,000 | 721,339,000 |
| Jun 2026 | 218,375,000 | 204,811,000 | -51,142,000 | -51,314,000 | 761,447,000 | 319,850,000 | 678,143,000 |
| Mar 2026 | 191,203,000 | 176,478,000 | -62,767,000 | -64,542,000 | 713,607,000 | 305,106,000 | 659,020,000 |
| Dec 2025 | 195,999,000 | 183,670,000 | -36,025,000 | -28,559,000 | 689,805,000 | 322,933,000 | 601,510,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,774,000
Investing CF
$-839,000
Financing CF
$71,200,000
CapEx
$-839,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.06
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,434,694,000
Inventory
$42,579,000
Receivables
$343,114,000
ST Investments
—
EBIT TTM
$-151,028,000
Pretax Income TTM
$-156,646,000
Interest Exp TTM
$5,618,000
Analysts
21
Yahoo Snapshot (yfinance, live)
Total Revenue
$865,267,968
EBITDA
$-152,798,000
Free Cash Flow
$-24,377,250
Enterprise Value
$6,873,026,048
Total Cash
$313,859,008
Total Debt
$224,224,992
Shares Out
52,599,985
Trailing EPS
$-3.03
Book Value
$2.00
ROE
-175.6%
ROA
-13.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 638,496,000 | -169,235,000 | -183,174,000 | 689,805,000 | 601,510,000 | 88,295,000 | -93,405,000 |
| Dec 2024 | 385,693,000 | -252,438,000 | -287,216,000 | 568,498,000 | 511,483,000 | 57,015,000 | -128,410,000 |
| Dec 2023 | 270,600,000 | -182,907,000 | -239,238,000 | 588,236,000 | 397,259,000 | 190,977,000 | -145,080,000 |
| Dec 2022 | 50,037,000 | -176,501,000 | -187,134,000 | 331,476,000 | 221,920,000 | 109,556,000 | -116,511,000 |
TTM Snapshot
Revenues TTM
$776,569,000
NetIncome TTM
$-191,644,000
OpCashFlow TTM
—
Assets (Latest)
$761,447,000
Forward EPS
$3.38
Max Pain — expiry 2027-01-15
max pain strike: $160.00 · spot: $134.00 · call oi: 2,792 · put oi: 3,815
Expected Move to 2027-01-15:
±$29.92
(22.33%) —
implied range
$104.08 –
$163.92
· ATM straddle on $135.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABVX | Abivax S.A. | $7.16B | $82.10 | — |
| CYTK | CYTOKINETICS INC | $7.20B | $51.65 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $7.36B | $21.12 | — |
| ALKS | Alkermes plc. | $7.64B | $45.45 | — |
| CORT | CORCEPT THERAPEUTICS INC | $7.67B | $70.07 | — |
News headlines (Yahoo Finance, 1h cache)
Axsome Therapeutics to Participate in Upcoming Investor Conferences
2026-11-19 12:00 · Yahoo
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch
2026-11-16 14:13 · Yahoo
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
2026-11-14 16:32 · Yahoo
Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years
2026-11-11 23:26 · Yahoo
Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge
2026-11-10 04:14 · Yahoo
Is Axsome Therapeutics (AXSM) Fully Priced Given Its Sales Growth?
2026-11-07 05:21 · Yahoo
Axsome Therapeutics (AXSM) Stock Gets Fair Value Trim After Q3 Analyst Revisions
2026-11-06 11:13 · Yahoo
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-05 19:37 · Yahoo
Axsome: 3 Key Takeaways for Long-Term Investors
2026-11-04 14:29 · Yahoo
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
2026-11-03 17:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.